Real-word evidence on healthcare resource use and associated costs in on-demand users of replacement therapies in von Willebrand disease in France: the FORvWARD study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background: Real-world data about use of Von Willebrand factor (VWF) concentrates to manage on-demand patients with Von Willebrand disease (VWD) are scarce. Aim: To describe and compare patients' characteristics, treatment patterns, healthcare resource use and associated costs of patients with VWD using VWF concentrates. Materials & methods: Using the French healthcare claims database, we included adult patients with ≥1 reimbursement for a replacement therapy (RT) containing VWF concentrate between 1 January 2017 and 30 September 2021 and followed them from first RT dispensation to 31 December 2021. Treatment patterns, healthcare resource use and associated costs of RT on-demand users were evaluated over each 30-days exposure period (EP) starting the first day of each hospital stay with ≥1 RT administration. In- and out-hospital RT doses and FVIII, number of general practitioner and nurse visits, in- and out-hospital RT dispensings and length of hospitalizations and their costs were described and compared across RTs using adjusted Generalized Estimating Equation models accounting for confounding factors. Results: Among 2540 on-demand RT users, WILFACTIN ® was the main RT used, followed by VONCENTO ® , VEYVONDI ® , EQWILATE ® and WILSTART ® . Overall, the mean total RT dose was 12,962 IU and the mean cost was €21,034/EP. Compared with VEYVONDI ® -treated EP, WILFACTIN ® -treated EP had significantly longer stay duration, had more out-hospital RT dose and had higher overall and in-hospital costs; VONCENTO ® -treated EP had more overall and in-hospital RT dose, and had higher in-hospital and RT-related costs. Conclusion: This first real-world study suggests that VEYVONDI ® seems to be a cost-saving RT compared with other RT. Future studies including clinical data should provide further evidence.
Institutions: Centre National de la Recherche Scientifique, Translational Innovation in Medicine and Complexity, Université Grenoble Alpes, Inserm, Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique, Université de Franche-Comté, Centre Hospitalier Universitaire de Nantes, Centre Hospitalier Universitaire de Montpellier, Takeda (France), École Supérieure des Sciences Économiques et Commerciales
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7140088455
FWCI:
Cites:
Cited by:
Related to: